» Articles » PMID: 38255895

Nrf2 Pathway and Oxidative Stress As a Common Target for Treatment of Diabetes and Its Comorbidities

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Jan 23
PMID 38255895
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetes is a chronic disease that induces many comorbidities, including cardiovascular disease, nephropathy, and liver damage. Many mechanisms have been suggested as to how diabetes leads to these comorbidities, of which increased oxidative stress in diabetic patients has been strongly implicated. Limited knowledge of antioxidative antidiabetic drugs and substances that can address diabetic comorbidities through the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway calls for detailed investigation. This review will describe how diabetes increases oxidative stress, the general impact of that oxidative stress, and how oxidative stress primarily contributes to diabetic comorbidities. It will also address how treatments for diabetes, especially focusing on their effects on the Nrf2 antioxidative pathway, have been shown to similarly affect the Nrf2 pathway of the heart, kidney, and liver systems. This review demonstrates that the Nrf2 pathway is a common pathogenic component of diabetes and its associated comorbidities, potentially identifying this pathway as a target to guide future treatments.

Citing Articles

KEAP1-NRF2/HO-1 Pathway Promotes Ferroptosis and Neuronal Injury in Schizophrenia.

Zhu F, Dan T, Hua S Brain Behav. 2025; 15(3):e70311.

PMID: 40021790 PMC: 11870791. DOI: 10.1002/brb3.70311.


Nrf2 Activation as a Therapeutic Target for Flavonoids in Aging-Related Osteoporosis.

Messeha S, Fidudusola F, Gendy S, Latinwo L, Odewumi C, Soliman K Nutrients. 2025; 17(2).

PMID: 39861398 PMC: 11767473. DOI: 10.3390/nu17020267.


Retinal Inflammation and Reactive Müller Cells: Neurotrophins' Release and Neuroprotective Strategies.

Balzamino B, Cacciamani A, Dinice L, Cecere M, Pesci F, Ripandelli G Biology (Basel). 2025; 13(12.

PMID: 39765697 PMC: 11673524. DOI: 10.3390/biology13121030.


Advances in the study of artemisinin and its derivatives for the treatment of rheumatic skeletal disorders, autoimmune inflammatory diseases, and autoimmune disorders: a comprehensive review.

Long Z, Xiang W, Xiao W, Min Y, Qu F, Zhang B Front Immunol. 2024; 15:1432625.

PMID: 39524446 PMC: 11543433. DOI: 10.3389/fimmu.2024.1432625.


Total flavonoids of (P. Beauv.) Spring ameliorates diabetes-induced acute lung injury via activating Nrf2/HO-1.

Chen L, Xiao G, Yu Z, Huang N, Cheng Y Iran J Basic Med Sci. 2024; 27(11):1423-1429.

PMID: 39386236 PMC: 11459338. DOI: 10.22038/ijbms.2024.79246.17166.


References
1.
Jin J, Zhang H, Cao Y, Liu H, Hua Q, Li Y . Association of small dense low-density lipoprotein with cardiovascular outcome in patients with coronary artery disease and diabetes: a prospective, observational cohort study. Cardiovasc Diabetol. 2020; 19(1):45. PMC: 7118853. DOI: 10.1186/s12933-020-01015-6. View

2.
Cuadrado A, Manda G, Hassan A, Alcaraz M, Barbas C, Daiber A . Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach. Pharmacol Rev. 2018; 70(2):348-383. DOI: 10.1124/pr.117.014753. View

3.
Andersen M, Ersboll M, Axelsson A, Gustafsson F, Hassager C, Kober L . Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) trial. Circulation. 2013; 127(11):1200-8. DOI: 10.1161/CIRCULATIONAHA.112.000056. View

4.
Vikramadithyan R, Hu Y, Noh H, Liang C, Hallam K, Tall A . Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J Clin Invest. 2005; 115(9):2434-43. PMC: 1190371. DOI: 10.1172/JCI24819. View

5.
Chiasson J, Josse R, Gomis R, Hanefeld M, Karasik A, Laakso M . Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003; 290(4):486-94. DOI: 10.1001/jama.290.4.486. View